1. Home
  2. LSAK vs EYPT Comparison

LSAK vs EYPT Comparison

Compare LSAK & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lesaka Technologies Inc.

LSAK

Lesaka Technologies Inc.

HOLD

Current Price

$4.20

Market Cap

411.8M

Sector

Finance

ML Signal

HOLD

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$3.84

Market Cap

419.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
LSAK
EYPT
Founded
1997
1987
Country
South Africa
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
411.8M
419.9M
IPO Year
2005
2005

Fundamental Metrics

Financial Performance
Metric
LSAK
EYPT
Price
$4.20
$3.84
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$31.80
AVG Volume (30 Days)
90.0K
4.0M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
102.63
N/A
EPS
0.03
N/A
Revenue
$721,554,000.00
$7,539,000.00
Revenue This Year
$14.35
N/A
Revenue Next Year
$8.60
$3,115.57
P/E Ratio
$141.33
N/A
Revenue Growth
9.38
N/A
52 Week Low
$3.62
$3.42
52 Week High
$5.54
$19.11

Technical Indicators

Market Signals
Indicator
LSAK
EYPT
Relative Strength Index (RSI) 35.81 31.98
Support Level N/A $3.95
Resistance Level $4.99 $14.72
Average True Range (ATR) 0.18 0.32
MACD -0.02 0.22
Stochastic Oscillator 15.00 39.33

Price Performance

Historical Comparison
LSAK
EYPT

About LSAK Lesaka Technologies Inc.

Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates three reportable segments: Merchant, Consumer and Enterprise. Merchant, which focuses on both formal and informal sector merchants. Consumer, which focuses on individuals who have historically been excluded from traditional financial services and to whom it offers transactional accounts (banking), insurance, lending (short-term loans), payments solutions and various value-added services; and Enterprise, which comprises large-scale corporate and government organizations, including but not limited to banks, mobile network operators (MNOs) and municipalities, and, through Recharger, landlords utilizing Recharger's prepaid electricity metering solution.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: